Joshua M. Eizen - 10 Jul 2024 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role
Chief Legal Officer
Signature
/s/ Lucy Day, Attorney-in-Fact for Joshua M. Eizen
Issuer symbol
ANTX
Transactions as of
10 Jul 2024
Net transactions value
$0
Form type
4
Filing time
12 Jul 2024, 16:13:01 UTC
Previous filing
29 Mar 2024
Next filing
05 Nov 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANTX Common Stock Award $0 +60,000 +172% $0.000000 94,833 10 Jul 2024 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a grant of restricted stock units ("RSUs"). RSUs vest as follows: 25% vest on January 1, 2025, 50% vest on January 1, 2026 and 25% vest on July 1, 2026, subject to the Reporting Person's continuous service as of such date.
F2 Includes a balance of 30,000 RSUs which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date.
F3 Reflects the adjusted total which includes the purchase of 2,386 shares under the Issuer's 2022 Employee Stock Purchase Plan on March 31, 2024.

Remarks:

Exhibits: Power of Attorney